Cambrex completes acquisition of Halo Pharma

The deal strengthens formulation development and finished dosage manufacturing capabilities to Cambrex's global API manufacturing network

Cambrex Corporation, the US manufacturer of small molecule APIs, has completed the acquisition of Halo Pharma. A CDMO specialist in dosage form, Halo operates facilities in Whippany, New Jersey (US) and Mirabel, Québec (Canada). Cambrex said the transaction is worth nearly US$425m. The deal was announced in July this year.

Shawn Cavanagh, COO of Cambrex, commented: “This acquisition expands our manufacturing footprint with the addition of two state-of-the-art, GMP compliant manufacturing facilities in North America, both with a strong reputation for quality and excellent track records with regulatory approvals from the US FDA, EMEA, DEA and Health Canada. We look forward to welcoming the 450-person workforce in joining our existing 1,200 experts across the United States and Europe and to continue to build long-term partnerships with our customers.”

The addition of Halo's facilities adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

The newly acquired Cambrex Whippany and Cambrex Mirabel provide formulation development and clinical and commercial manufacturing services, specialising in oral solids, liquids, creams, sterile and non-sterile ointments.

The facilities’ core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for pediatric indications and controlled substances.

“The acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combined business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” commented Steve Klosk, President and CEO of Cambrex.